Amgen, Allergan launch first anti-cancer biosims in U.S.
Amgen and Allergan have announced the launch of Mvasi, a bevacizumab biosimilar referencing Avastin, and Kanjinti, a trastuzumab biosimilar referencing Herceptin, in the United States. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 19, 2019 Category: Pharmaceuticals Source Type: news
Avastin Improves Quality of Life for Mesothelioma Patients
A research team from France has documented the health-related quality-of-life benefits of adding Avastin (bevacizumab) to chemotherapy for pleural mesothelioma patients, endorsing its addition to standard-of-care treatment.
The recent quality-of-life analysis was a secondary endpoint of an earlier, multicenter clinical trial in France that showed an almost three-month median survival improvement when adding Avastin.
The latest study demonstrated that adding Avastin to cisplatin and Alimta (pemetrexed) did not negatively impact quality of life — a problem with several other cancers because of the increased toxicity.
“Co...
Source: Asbestos and Mesothelioma News - July 8, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Zirabev (Bevacizumab-bvzr Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 8, 2019 Category: Drugs & Pharmacology Source Type: news
Mvasi (Bevacizumab-awwb Solution for Intravenous Infusion) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 8, 2019 Category: Drugs & Pharmacology Source Type: news
Pfizer's Avastin biosimilar wins FDA approval
Pfizer Inc said on Friday that the U.S. Food and Drug Administration had approved its biosimilar to Roche Holding AG's blockbuster cancer treatment Avastin. (Source: Reuters: Health)
Source: Reuters: Health - June 28, 2019 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin
Friday, June 28, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved Zirabev (bevacizumab-bvzr), a biosimilar to Avastin® (bevacizumab),1 for the treatment of five types... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 28, 2019 Category: Drugs & Pharmacology Source Type: news
Discouraging OS Results With Bevacizumab in Ovarian Cancer
Long-term follow-up of a phase III trial showed overall survival results for bevacizumab plus chemotherapy in women with ovarian, fallopian tube, or primary peritoneal cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news
RXQ Compounding Recalls All'Sterile' Product RXQ Compounding Recalls All'Sterile' Product
Sterility concerns prompt RXQ Compounding to recall all unexpired sterile products, including injectable bevacizumab, epinephrine, ketamine, fentanyl, and midazolam, among others.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2019 Category: Consumer Health News Tags: Hospital Medicine News Alert Source Type: news
Adding Bevacizumab Improves Overall Survival in NSCLC
Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non - small cell lung cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 18, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Pulmonology, Journal, Source Type: news
Adding Bevacizumab Improves Overall Survival in NSCLC
TUESDAY, June 18, 2019 -- The addition of bevacizumab to carboplatin/pemetrexed is associated with improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to a study published in the May issue of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 18, 2019 Category: Pharmaceuticals Source Type: news
Identifying colorectal cancer subtypes could lead to improved treatment decisions
(University of Southern California - Health Sciences) Identifying a metastatic colorectal cancer patient's Consensus Molecular Subtype could help oncologists determine the most effective course of treatment. For example, Survival for CMS1 patients on bevacizumab was twice that of those on cetuximab, whereas survival for CMS2 patients on cetuximab was six months longer than for bevacizumab. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 12, 2019 Category: International Medicine & Public Health Source Type: news
Dr. Ramalingam on Pemetrexed and Bevacizumab as Maintenance Therapy for Advanced NSCLC
Cancer Network spoke with Suresh S. Ramalingam, MD, of Emory University, about pemetrexed, bevacizumab, or both for advanced non-squamous NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Suresh S. Ramalingam, MD Source Type: news
Effect of Anti-Angiogenesis/Immunotherapy Combo in Poor-Risk RCC
Findings from a planned subanalysis of IMmotion151 looked at combination atezolizumab and bevacizumab in patients with RCC and sarcomatoid histology. (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
Patient Outcomes for Atezolizumab vs Sunitinib in Renal Cell Carcinoma
The phase II IMmotion150 study evaluated disease- and treatment-related symptoms in RCC patients receiving atezolizumab alone or in combination with bevacizumab vs sunitinib. (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
Addition of Maintenance Therapy Did Not Meet Primary Endpoint in Lung Cancer Trial
The addition of pemetrexed to bevacizumab maintenance therapy after induction therapy for chemo-naive patients with advanced lung cancer did not meet the primary endpoint in a phase III trial. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
